Akihiro Nomura

Akihiro Nomura

Auto-generated profile, based on publicly available information

Akihiro Nomura

College of Transdisciplinary Sciences for Innovation, Kanazawa University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
KKKazuomi Kario
Kazuomi Kario
ANAkihiro Nomura
Akihiro Nomura
NHNoriko Harada
Noriko Harada
AOAyako Okura
Ayako Okura
KNKiyose Nakagawa
Kiyose Nakagawa
EHEisuke Hida
Eisuke Hida
Digital therapeutics is a new approach to facilitate the non-pharmacological treatment of hypertension using software programmes such as smartphone applications and/or device algorithms. Based on promising findings from a small pilot trial, the HERB Digital Hypertension 1 (HERB-DH1) pivotal trial investigated the efficacy of digital therapeutics in patients with hypertension not receiving antihypertensive medication. This prospective, open-label, randomized controlled study was performed at 12 sites in Japan. Patients with hypertension [office systolic blood pressure (SBP) 140 to <180 mmHg and 24 h SBP ≥130 mmHg] were randomly assigned 1:1 to the digital therapeutics group (HERB system + standard lifestyle modification) or control group (standard lifestyle modification alone). The primary efficacy endpoint was the mean change in 24 h ambulatory SBP from baseline to 12 weeks; key secondary efficacy endpoints were mean changes in office and home blood pressure (BP) from baseline to 12 weeks. All analyses were conducted in the full analysis set population. Between December 2019 and June 2020, 390 patients were randomly assigned to the digital therapeutics group (n = 199) or control (n = 191) group. Between-group differences in 24-h ambulatory, home, and office SBPs at 12 weeks were −2.4 (95% confidence interval −4.5 to −0.3), −4.3 (−6.7 to −1.9), and −3.6 (−6.2 to −1.0) mmHg, respectively. No major programme-related safety events occurred up to 24 weeks. The HERB-DH1 pivotal study showed the superiority of digital therapeutics compared with standard lifestyle modification alone to reduce 24-h ambulatory, home, and office BPs in the absence of antihypertensive medications.

13 December 2021 in Current Diabetes Reports
Verified
Journal Article
Open access
PDF file
ANAkihiro Nomura
Akihiro Nomura
MNMasahiro Noguchi
Masahiro Noguchi
MKMitsuhiro Kometani
Mitsuhiro Kometani
KFKenji Furukawa
Kenji Furukawa
TYTakashi Yoneda
Takashi Yoneda
Purpose of Review: Artificial intelligence (AI) can make advanced inferences based on a large amount of data. The mainstream technologies of the AI boom in 2021 are machine learning (ML) and deep learning, which have made significant progress due to the increase in computational resources accompanied by the dramatic improvement in computer performance. In this review, we introduce AI/ML-based medical devices and prediction models regarding diabetes. Recent Findings: In the field of diabetes, several AI-/ML-based medical devices and regarding automatic retinal screening, clinical diagnosis support, and patient self-management tool have already been approved by the US Food and Drug Administration. As for new-onset diabetes prediction using ML methods, its performance is not superior to conventional risk stratification models that use statistical approaches so far. Summary: Despite the current situation, it is expected that the predictive performance of AI will soon be maximized by a large amount of organized data and abundant computational resources, which will contribute to a dramatic improvement in the accuracy of disease prediction models for diabetes.

23 January 2024 in PLOS Digital Health
Verified
Journal Article
Open access
PDF file
YTYudai Tanaka
Yudai Tanaka
TNTakuto Nakata
Takuto Nakata
KAKo Aiga
Ko Aiga
TETakahide Etani
Takahide Etani
RMRyota Muramatsu
Ryota Muramatsu
ANAkihiro Nomura
Akihiro Nomura
The remarkable performance of ChatGPT, launched in November 2022, has significantly impacted the field of natural language processing, inspiring the application of large language models as supportive tools in clinical practice and research worldwide. Although GPT-3.5 recently scored high on the United States Medical Licensing Examination, its performance on medical licensing examinations of other nations, especially non-English speaking nations, has not been sufficiently evaluated. This study assessed GPT’s performance on the National Medical Licensing Examination (NMLE) in Japan and compared it with the actual minimal passing rate for this exam. In particular, the performances of both the GPT-3.5 and GPT-4 models were considered for the comparative analysis. We initially used the GPT models and several prompts for 290 questions without image data from the 116th NMLE (held in February 2022 in Japan) to maximize the performance for delivering correct answers and explanations of the questions. Thereafter, we tested the performance of the best GPT model (GPT-4) with optimized prompts on a dataset of 262 questions without images from the latest 117th NMLE (held in February 2023). The best model with the optimized prompts scored 82.7% for the essential questions and 77.2% for the basic and clinical questions, both of which sufficed the minimum passing scoring rates of 80.0% and 74.6%, respectively. After an exploratory analysis of 56 incorrect answers from the model, we identified the three major factors contributing to the generation of the incorrect answers—insufficient medical knowledge, information on Japan-specific medical system and guidelines, and mathematical errors. In conclusion, GPT-4 with our optimized prompts achieved a minimum passing scoring rate in the latest 117th NMLE in Japan. Beyond its original design of answering examination questions for humans, these artificial intelligence (AI) models can serve as one of the best “sidekicks” for solving problems and addressing the unmet needs in the medical and healthcare fields.

26 April 2019 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ANAkihiro Nomura
Akihiro Nomura
TTTomoyuki Tanigawa
Tomoyuki Tanigawa
TMTomoyasu Muto
Tomoyasu Muto
TOTakafumi Oga
Takafumi Oga
YFYasushi Fukushima
Yasushi Fukushima
KSKohta Satake
Kohta Satake
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Tobacco is a major public health concern. A 12-week standard smoking cessation program is available in Japan; however, its required face-to-face clinic visits has been one of the key obstacles to completing the program, leading to a low smoking cessation success rate. Telemedicine using an internet-based video counseling instead of regular clinic visits could address the obstacles. Objective: This study aimed to evaluate the efficacy and feasibility of an internet-based remote smoking cessation support program compared with the standard face-to-face clinical visit program among patients with nicotine dependence. Methods: This study was a randomized, controlled, open-label, multi-center, non-inferiority trial. We recruited nicotine-dependent adults from March to June 2018. Participants randomized to the telemedicine arm underwent an internet-based video counseling, whereas control participants underwent standard face-to-face clinical visits at each time point on the smoking cessation program. Both arms received a CureApp Smoking Cessation smartphone application with a mobile exhaled carbon monoxide checker. The primary outcome was a continuous abstinence rate (CAR) at weeks 9–12. We conducted all analyses by full analysis set. Results: We randomized 115 participants with nicotine dependence: 58 were allocated to the telemedicine (internet-based video counseling) arm and 57, to the control (standard face-to-face clinical visit) arm. We analyzed all 115 participants for the primary outcome. Both telemedicine and control groups had similar CARs at weeks 9–12 (telemedicine vs. control, 81.0% vs. 78.9%; absolute difference, 2.1%; 95% confidence interval, -12.8 to 17.0); the lower limit of the difference between groups (-12.8%) was greater than a pre-specified limit (-15%). Conclusions: The application of telemedicine using internet-based video counseling as a smoking cessation program had a similar CAR at weeks 9–12 as the standard face-to-face clinical visit program. The efficacy of the telemedicine-based smoking cessation program was non-inferior to that of the standard visit-based smoking cessation program. Clinical Trial: This trial was registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN ID: UMIN000031620).

30 August 2020 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
PDF file
ANAkihiro Nomura
Akihiro Nomura
CEConnor A. Emdin
Connor A. Emdin
HWHong Hee Won
Hong Hee Won
GPGina M. Peloso
Gina M. Peloso
PNPradeep Natarajan
Pradeep Natarajan
SKSekar Kathiresan
Sekar Kathiresan
Background: Familial sitosterolemia is a rare Mendelian disorder characterized by hyperabsorption and decreased biliary excretion of dietary sterols. Affected individuals typically have complete genetic deficiency—homozygous loss-of-function (LoF) variants—in theABCG5orABCG8genes and have substantially elevated plasma sitosterol and LDL (low-density lipoprotein) cholesterol (LDL-C) levels. The impact of partial genetic deficiency ofABCG5orABCG8—as occurs in heterozygous carriers of LoF variants—on LDL-C and risk of coronary artery disease (CAD) has remained uncertain.Methods: We first recruited 9 sitosterolemia families, identified causative LoF variants inABCG5orABCG8, and evaluated the associations of theseABCG5orABCG8LoF variants with plasma phytosterols and lipid levels. We next assessed for LoF variants inABCG5orABCG8in CAD cases (n=29 321) versus controls (n=357 326). We tested the association of rare LoF variants inABCG5orABCG8with blood lipids and risk for CAD. Rare LoF variants were defined as protein-truncating variants with minor allele frequency <0.1% inABCG5orABCG8.Results: In sitosterolemia families, 7 pedigrees harbored causative LoF variants inABCG5and 2 pedigrees inABCG8. Homozygous LoF variants in eitherABCG5orABCG8led to marked elevations in sitosterol and LDL-C. Of those sitosterolemia families, heterozygous carriers ofABCG5LoF variants exhibited increased sitosterol and LDL-C levels compared with noncarriers. Within large-scale CAD case-control cohorts, prevalence of rare LoF variants inABCG5and inABCG8was ≈0.1% each.ABCG5heterozygous LoF variant carriers had significantly elevated LDL-C levels (25 mg/dL [95% CI, 14–35];P=1.1×10−6) and were at 2-fold increased risk of CAD (odds ratio, 2.06 [95% CI, 1.27–3.35];P=0.004). By contrast,ABCG8heterozygous LoF carrier status was not associated with increased LDL-C or risk of CAD.Conclusions: Although familial sitosterolemia is traditionally considered as a recessive disorder, we observed that heterozygous carriers of an LoF variant inABCG5had significantly increased sitosterol and LDL-C levels and a 2-fold increase in risk of CAD.

19 February 2019 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
KMKatsunori Masaki
Katsunori Masaki
HTHiroki Tateno
Hiroki Tateno
NKNaofumi Kameyama
Naofumi Kameyama
EMEriko Morino
Eriko Morino
RWRiri Watanabe
Riri Watanabe
KFKoichi Fukunaga
Koichi Fukunaga
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Mobile applications have been considered to provide active and continuous support for smoking cessation. However, it is yet to be known whether a smoking cessation smartphone application improves long-term abstinence rates in nicotine-dependent patients. Objective: We aim to evaluate the long-term abstinence effect of a novel smartphone application, CureApp Smoking Cessation (CASC), in patients with nicotine dependence. Methods: This study was a prospective, interventional, multicenter, single-arm study. We provided the CASC application to all the participants, who used it daily for 24 weeks. The CASC application includes features to maximize the therapeutic effect of pharmacological therapies and counseling at outpatient clinics for smoking cessation. The primary endpoint was a continuous abstinence rate (CAR) from weeks 9 to 24, while secondary endpoints were CARs from weeks 9 to 12 and 9 to 52. Results: Of the 56 adult smokers recruited, one did not download the application; therefore, 55 participants constituted the full analysis sample. The CAR from weeks 9 to 24 was 63.6% (35/55; 95% confidence interval [CI]: 51.3% – 76.0%), while the CARs from weeks 9 to 12 and 9 to 52 were 76.4% (42/55; 95% CI: 65.2% – 87.5%) and 58.2% (32/55; 95% CI: 45.6% – 70.8%), respectively. These CARs were better than the results of the national survey on outpatient clinics with regard to smoking cessation under the National Health Insurance Program and that of the varenicline phase Ⅲ trial in Japan and the United States. There was only one participant who dropped out during the 12 weeks of the treatment period. This treatment decreased the scores related to withdrawal and craving symptoms. Conclusions: The addition of CASC to usual smoking cessation therapies resulted in high CARs, high patient retention rates, and improvement of cessation-related symptoms. The smartphone application CASC is a feasible and useful tool to help long-term continuous abstinence that can be combined with a standard smoking cessation treatment program. Clinical Trial: University Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN ID: UMIN000020123).